EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹214 Cr
Expense Ratio
0.47%
ISIN
INF00XX01BO9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
11 Nov 2021
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+18.55%
+17.55% (Cat Avg.)
3 Years
+20.04%
+18.10% (Cat Avg.)
Since Inception
+16.54%
— (Cat Avg.)
Equity | ₹209.4 Cr | 97.95% |
Others | ₹4.37 Cr | 2.05% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹34.67 Cr | 16.22% |
Divi's Laboratories Ltd | Equity | ₹12.74 Cr | 5.96% |
Lupin Ltd | Equity | ₹12.35 Cr | 5.78% |
Suven Pharmaceuticals Ltd | Equity | ₹11.52 Cr | 5.39% |
Apollo Hospitals Enterprise Ltd | Equity | ₹11.03 Cr | 5.16% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹10.83 Cr | 5.07% |
Torrent Pharmaceuticals Ltd | Equity | ₹8.79 Cr | 4.11% |
Aurobindo Pharma Ltd | Equity | ₹7.71 Cr | 3.61% |
Mankind Pharma Ltd | Equity | ₹6.6 Cr | 3.09% |
Alkem Laboratories Ltd | Equity | ₹6.08 Cr | 2.84% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹6.02 Cr | 2.81% |
Abbott India Ltd | Equity | ₹5.19 Cr | 2.43% |
Neuland Laboratories Limited | Equity | ₹4.87 Cr | 2.28% |
Net Receivables / (Payables) | Cash | ₹4.37 Cr | 2.05% |
Granules India Ltd | Equity | ₹4.26 Cr | 1.99% |
Dr Reddy's Laboratories Ltd | Equity | ₹4.08 Cr | 1.91% |
Wockhardt Ltd | Equity | ₹4.05 Cr | 1.90% |
HealthCare Global Enterprises Ltd | Equity | ₹3.68 Cr | 1.72% |
Supriya Lifescience Ltd | Equity | ₹3.65 Cr | 1.71% |
Fortis Healthcare Ltd | Equity | ₹3.34 Cr | 1.56% |
Sumitomo Chemical India Ltd Ordinary Shares | Equity | ₹3.24 Cr | 1.52% |
FDC Ltd | Equity | ₹3.07 Cr | 1.44% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹2.97 Cr | 1.39% |
Rainbow Childrens Medicare Ltd | Equity | ₹2.82 Cr | 1.32% |
Orchid Pharma Ltd | Equity | ₹2.81 Cr | 1.32% |
Caplin Point Laboratories Ltd | Equity | ₹2.65 Cr | 1.24% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹2.63 Cr | 1.23% |
Gland Pharma Ltd | Equity | ₹2.62 Cr | 1.22% |
Emcure Pharmaceuticals Ltd | Equity | ₹2.5 Cr | 1.17% |
Sai Life Sciences Ltd | Equity | ₹2.26 Cr | 1.06% |
Vijaya Diagnostic Centre Ltd | Equity | ₹2.25 Cr | 1.05% |
Cipla Ltd | Equity | ₹2.22 Cr | 1.04% |
OneSource Specialty Pharma Ltd | Equity | ₹2.19 Cr | 1.03% |
Shilpa Medicare Ltd | Equity | ₹2.19 Cr | 1.02% |
SRF Ltd | Equity | ₹2.1 Cr | 0.98% |
UPL Ltd | Equity | ₹2.04 Cr | 0.95% |
Linde India Ltd | Equity | ₹1.96 Cr | 0.92% |
Sequent Scientific Ltd | Equity | ₹1.95 Cr | 0.91% |
Strides Pharma Science Ltd | Equity | ₹1.84 Cr | 0.86% |
Laurus Labs Ltd | Equity | ₹1.59 Cr | 0.74% |
Large Cap Stocks
29.24%
Mid Cap Stocks
33.78%
Small Cap Stocks
31.63%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹195.18 Cr | 91.30% |
Basic Materials | ₹7.25 Cr | 3.39% |
Industrials | ₹2.1 Cr | 0.98% |
Standard Deviation
This fund
16.41%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
0.83
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since December 2022
Since November 2021
ISIN INF00XX01BO9 | Expense Ratio 0.47% | Exit Load 1.00% | Fund Size ₹214 Cr | Age 3 years 5 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
ITI Focused Equity Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹478.53 Cr | 12.4% |
ITI Liquid Fund Direct Growth Low to Moderate Risk | 0.1% | 0.0% | ₹48.22 Cr | 7.2% |
ITI Ultra Short Duration Fund Direct Growth Low to Moderate Risk | 0.2% | 0.0% | ₹180.28 Cr | 7.6% |
ITI Multi Cap Fund Direct Growth Very High Risk | 0.3% | 1.0% | ₹1116.36 Cr | 3.0% |
ITI Value Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹297.69 Cr | 2.4% |
ITI Conservative Hybrid Fund Direct Growth Moderate Risk | 0.2% | 0.0% | ₹14.80 Cr | 8.9% |
ITI Dynamic Bond Fund Direct Growth Moderate Risk | 0.1% | 0.0% | ₹39.64 Cr | 11.8% |
ITI Balanced Advantage Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹382.77 Cr | 6.8% |
ITI Small Cap Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹2219.20 Cr | 11.1% |
ITI Large Cap Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹472.57 Cr | 3.9% |
ITI Banking & PSU Debt Fund Direct Growth Moderate Risk | 0.1% | 0.0% | ₹34.80 Cr | 9.2% |
ITI Banking and Financial Services Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹287.76 Cr | 17.0% |
ITI Arbitrage Fund Direct Growth Low Risk | 0.2% | 0.0% | ₹47.67 Cr | 7.8% |
ITI Overnight Fund Direct Growth Low Risk | 0.1% | 0.0% | ₹21.96 Cr | 6.4% |
ITI Mid Cap Fund Direct Growth Very High Risk | 0.2% | 1.0% | ₹1091.64 Cr | 7.1% |
ITI Long Term Equity Fund Direct Growth Very High Risk | 0.6% | 0.0% | ₹377.68 Cr | 7.7% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹213.77 Cr | 18.5% |
ITI Flexi Cap Fund Direct Growth Very High Risk | 0.2% | 1.0% | ₹1031.77 Cr | 8.2% |
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹214 Cr
Expense Ratio
0.47%
ISIN
INF00XX01BO9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
11 Nov 2021
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+18.55%
+17.55% (Cat Avg.)
3 Years
+20.04%
+18.10% (Cat Avg.)
Since Inception
+16.54%
— (Cat Avg.)
Equity | ₹209.4 Cr | 97.95% |
Others | ₹4.37 Cr | 2.05% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹34.67 Cr | 16.22% |
Divi's Laboratories Ltd | Equity | ₹12.74 Cr | 5.96% |
Lupin Ltd | Equity | ₹12.35 Cr | 5.78% |
Suven Pharmaceuticals Ltd | Equity | ₹11.52 Cr | 5.39% |
Apollo Hospitals Enterprise Ltd | Equity | ₹11.03 Cr | 5.16% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹10.83 Cr | 5.07% |
Torrent Pharmaceuticals Ltd | Equity | ₹8.79 Cr | 4.11% |
Aurobindo Pharma Ltd | Equity | ₹7.71 Cr | 3.61% |
Mankind Pharma Ltd | Equity | ₹6.6 Cr | 3.09% |
Alkem Laboratories Ltd | Equity | ₹6.08 Cr | 2.84% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹6.02 Cr | 2.81% |
Abbott India Ltd | Equity | ₹5.19 Cr | 2.43% |
Neuland Laboratories Limited | Equity | ₹4.87 Cr | 2.28% |
Net Receivables / (Payables) | Cash | ₹4.37 Cr | 2.05% |
Granules India Ltd | Equity | ₹4.26 Cr | 1.99% |
Dr Reddy's Laboratories Ltd | Equity | ₹4.08 Cr | 1.91% |
Wockhardt Ltd | Equity | ₹4.05 Cr | 1.90% |
HealthCare Global Enterprises Ltd | Equity | ₹3.68 Cr | 1.72% |
Supriya Lifescience Ltd | Equity | ₹3.65 Cr | 1.71% |
Fortis Healthcare Ltd | Equity | ₹3.34 Cr | 1.56% |
Sumitomo Chemical India Ltd Ordinary Shares | Equity | ₹3.24 Cr | 1.52% |
FDC Ltd | Equity | ₹3.07 Cr | 1.44% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹2.97 Cr | 1.39% |
Rainbow Childrens Medicare Ltd | Equity | ₹2.82 Cr | 1.32% |
Orchid Pharma Ltd | Equity | ₹2.81 Cr | 1.32% |
Caplin Point Laboratories Ltd | Equity | ₹2.65 Cr | 1.24% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹2.63 Cr | 1.23% |
Gland Pharma Ltd | Equity | ₹2.62 Cr | 1.22% |
Emcure Pharmaceuticals Ltd | Equity | ₹2.5 Cr | 1.17% |
Sai Life Sciences Ltd | Equity | ₹2.26 Cr | 1.06% |
Vijaya Diagnostic Centre Ltd | Equity | ₹2.25 Cr | 1.05% |
Cipla Ltd | Equity | ₹2.22 Cr | 1.04% |
OneSource Specialty Pharma Ltd | Equity | ₹2.19 Cr | 1.03% |
Shilpa Medicare Ltd | Equity | ₹2.19 Cr | 1.02% |
SRF Ltd | Equity | ₹2.1 Cr | 0.98% |
UPL Ltd | Equity | ₹2.04 Cr | 0.95% |
Linde India Ltd | Equity | ₹1.96 Cr | 0.92% |
Sequent Scientific Ltd | Equity | ₹1.95 Cr | 0.91% |
Strides Pharma Science Ltd | Equity | ₹1.84 Cr | 0.86% |
Laurus Labs Ltd | Equity | ₹1.59 Cr | 0.74% |
Large Cap Stocks
29.24%
Mid Cap Stocks
33.78%
Small Cap Stocks
31.63%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹195.18 Cr | 91.30% |
Basic Materials | ₹7.25 Cr | 3.39% |
Industrials | ₹2.1 Cr | 0.98% |
Standard Deviation
This fund
16.41%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
0.83
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since December 2022
Since November 2021
ISIN INF00XX01BO9 | Expense Ratio 0.47% | Exit Load 1.00% | Fund Size ₹214 Cr | Age 3 years 5 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
ITI Focused Equity Fund Direct Growth Very High Risk | 0.7% | 1.0% | ₹478.53 Cr | 12.4% |
ITI Liquid Fund Direct Growth Low to Moderate Risk | 0.1% | 0.0% | ₹48.22 Cr | 7.2% |
ITI Ultra Short Duration Fund Direct Growth Low to Moderate Risk | 0.2% | 0.0% | ₹180.28 Cr | 7.6% |
ITI Multi Cap Fund Direct Growth Very High Risk | 0.3% | 1.0% | ₹1116.36 Cr | 3.0% |
ITI Value Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹297.69 Cr | 2.4% |
ITI Conservative Hybrid Fund Direct Growth Moderate Risk | 0.2% | 0.0% | ₹14.80 Cr | 8.9% |
ITI Dynamic Bond Fund Direct Growth Moderate Risk | 0.1% | 0.0% | ₹39.64 Cr | 11.8% |
ITI Balanced Advantage Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹382.77 Cr | 6.8% |
ITI Small Cap Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹2219.20 Cr | 11.1% |
ITI Large Cap Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹472.57 Cr | 3.9% |
ITI Banking & PSU Debt Fund Direct Growth Moderate Risk | 0.1% | 0.0% | ₹34.80 Cr | 9.2% |
ITI Banking and Financial Services Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹287.76 Cr | 17.0% |
ITI Arbitrage Fund Direct Growth Low Risk | 0.2% | 0.0% | ₹47.67 Cr | 7.8% |
ITI Overnight Fund Direct Growth Low Risk | 0.1% | 0.0% | ₹21.96 Cr | 6.4% |
ITI Mid Cap Fund Direct Growth Very High Risk | 0.2% | 1.0% | ₹1091.64 Cr | 7.1% |
ITI Long Term Equity Fund Direct Growth Very High Risk | 0.6% | 0.0% | ₹377.68 Cr | 7.7% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹213.77 Cr | 18.5% |
ITI Flexi Cap Fund Direct Growth Very High Risk | 0.2% | 1.0% | ₹1031.77 Cr | 8.2% |
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments